<DOC>
	<DOCNO>NCT02347254</DOCNO>
	<brief_summary>The propose study evaluate safety initial effectiveness ExAblate Transcranial MRgFUS ) treatment patient L-dopa induce dyskinesia Parkinson 's disease ( LID PD ) . Safety : To evaluate incidence severity adverse event associate ExAblate Transcranial 4000 MRgFUS treatment dyskinesia Parkinson 's disease . Effectiveness : To determine level effectiveness ExAblate Transcranial MRgFUS treatment LID PD patient . Efficacy determine utilizing clinical rating scale dyskinesia ( UPDRS-IV Unified Dyskinesia Rating Scale ) examination Baseline , 3-Months 12-Months post-ExAblate treatment .</brief_summary>
	<brief_title>ExAblate Transcranial MRgFUS Unilateral Pallidotomy Treatment Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Men woman , 18 80 year , inclusive . Patients able willing give consent able attend study visit . Able communicate sensation ExAblate MRgFUS treatment Stable dos medication 30 day prior study entry duration study . Inclusion exclusion criterion agree upon two member medical team . Patients unstable cardiac status include : Unstable angina pectoris medication Patients document myocardial infarction within six month protocol entry Congestive heart failure require medication ( diuretic ) Patients antiarrhythmic drug Severe hypertension ( diastolic BP &gt; 100 medication ) Patients standard contraindication MR image nonMRI compatible implant metallic device include cardiac pacemaker , size limitation , etc . Known intolerance allergy MRI contrast agent ( e.g . Gadolinium Magnevist ) include advanced kidney disease Severely impaired renal function ( estimate glomerular filtration rate &lt; 30ml/min/1.73 m2 ) receive dialysis History abnormal bleeding and/or coagulopathy Cerebrovascular disease ( multiple CVA CVA within 6 month ) Symptoms sign increase intracranial pressure ( e.g . headache , nausea , vomit , lethargy , papilledema ) Active suspect acute chronic uncontrolled infection History intracranial hemorrhage Receiving anticoagulant ( e.g . warfarin ) antiplatelet ( e.g . aspirin ) therapy within one week focus ultrasound procedure drug know increase risk hemorrhage ( e.g . Avastin ) within one month focus ultrasound procedure Individuals able willing tolerate require prolonged stationary supine position treatment Are participate participate another clinical trial last 30 day Patients unable communicate investigator staff . Presence neurodegenerative disease like parkinsonplus syndrome suspect neurological examination . These include : multisystem atrophy , progressive supranuclear palsy , dementia Lewy body , Alzheimer 's disease . Presence significant cognitive impairment determine score &lt; = 24 Mini Mental Status Examination ( MMSE ) Patients history seizure within past year Patients psychiatric illness well control . Any presence psychosis exclude . Patients mood disorder include depression exclude exhibit symptom within 6 month medication . Patients treat transcranial magnetic stimulation ECT exclude . Patients risk factor intraoperative postoperative bleeding ( platelet count le 100,000 per cubic millimeter ) document coagulopathy Patients brain tumor Any illness investigator 's opinion preclude participation study . Pregnancy lactation . Patient unable provide consent reason . Legal incapacity limit legal capacity . Patients deep brain stimulation prior stereotactic ablation basal ganglia History immunocompromise , include patient HIV positive Known lifethreatening systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>